Page last updated: 2024-08-23

paclitaxel and Lymphoma, B-Cell, Marginal Zone

paclitaxel has been researched along with Lymphoma, B-Cell, Marginal Zone in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Hu, X; Wang, Z; Yuan, S; Zhao, Y	1

Other Studies

1 other study(ies) available for paclitaxel and Lymphoma, B-Cell, Marginal Zone

Article	Year
Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency. Frontiers in immunology, 2020, Volume: 11 Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Immunologic Factors; Lenalidomide; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Rituximab	2020

Article

Year

Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.

Frontiers in immunology, 2020, Volume: 11

Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Immunologic Factors; Lenalidomide; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Rituximab

2020